Jason Ladner to Ebola Vaccines
This is a "connection" page, showing publications Jason Ladner has written about Ebola Vaccines.
Connection Strength
0.388
-
Stromberg ZR, Silva EE, Johnston SC, Johnson DM, Hall D, Adjei EF, Altin JA, Abisoye-Ogunniyan A, Gollott T, He W, Jones IKA, Kwilas S, Lund SJ, Mead HL, Nelson GA, Ouyang L, Peters SKG, Schwedler JL, Trecazzi CZ, Turner MW, Ye C, Bradfute SB, Fischer NO, Hooper JW, Ladner JT, Rasley A, Negrete OA. An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models. Front Immunol. 2025; 16:1682418.
Score: 0.239
-
Mbala-Kingebeni P, Aziza A, Di Paola N, Wiley MR, Makiala-Mandanda S, Caviness K, Pratt CB, Ladner JT, Kugelman JR, Prieto K, Chitty JA, Larson PA, Beitzel B, Ayouba A, Vidal N, Karhemere S, Diop M, Diagne MM, Faye M, Faye O, Aruna A, Nsio J, Mulangu F, Mukadi D, Mukadi P, Kombe J, Mulumba A, Villabona-Arenas CJ, Pukuta E, Gonzalez J, Bartlett ML, Sozhamannan S, Gross SM, Schroth GP, Tim R, Zhao JJ, Kuhn JH, Diallo B, Yao M, Fall IS, Ndjoloko B, Mossoko M, Lacroix A, Delaporte E, Sanchez-Lockhart M, Sall AA, Muyembe-Tamfum JJ, Peeters M, Palacios G, Ahuka-Mundeke S. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. Lancet Infect Dis. 2019 06; 19(6):648-657.
Score: 0.150